Covid-19 roundup: Mer­ck, Ridge­back drop new analy­ses for mol­nupi­ravir; Veru sub­mits EUA for an­tivi­ral treat­ment

As Mer­ck and Ridge­back look to make their Covid an­tivi­ral more com­pet­i­tive to Pfiz­er’s Paxlovid, the com­pa­nies pub­lished ad­di­tion­al da­ta from their Phase III tri­al …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER